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Abstract 
Background: Intratumor heterogeneity has been demonstrated in several cancer types, following a model of 
branched evolution. It is unknown to which extent intratumor heterogeneity is applicable to esophageal adenocarci-
noma. Therefore the aim of this study was to characterise intratumor heterogeneity in esophageal adenocarcinoma.
Methods: Multiregional targeted sequencing of four commonly altered genes was performed on 19 tumor regions 
collected from five esophageal adenocarcinomas. Alterations were classified as homogeneous or heterogeneous 
based on mutational and loss of heterozygosity analysis.
Results: Identical TP53 mutations and homogeneously loss of heterozygosity of the TP53 locus were identified in all 
separated tumor regions in each of five adenocarcinomas, and in the corresponding Barrett’s esophagus and tumor 
positive lymph node of one primary tumor. Loss of heterozygosity of the P16 locus was homogeneous among all 
tumor regions in four adenocarcinomas, and an identical pattern of loss of heterozygosity was present in the Barrett’s 
esophagus. Loss of heterozygosity of the SMAD4 and APC loci was observed in a heterogeneous pattern.
Conclusions: Known driver alterations, such as TP53 and P16 are homogeneously present within each adenocar-
cinoma, and therefore occur early during carcinogenesis and subsequently clonally expand throughout the entire 
tumor. However, loss of heterozygosity of the SMAD4 and APC loci shows a heterogeneous pattern, indicating intratu-
mor heterogeneity of esophageal adenocarcinoma.
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Background
The incidence of esophageal adenocarcinoma (EAC) has 
been rising rapidly in Western countries over the last 
decades [1–3]. The major risk factor for EAC is Barrett’s 
esophagus (BE) [4], a premalignant condition, in which 
the normal squamous epithelium of the distal esopha-
gus has been replaced by columnar epithelium, includ-
ing goblet cells. The risk of developing EAC from BE is 
estimated at 0.12–0.5% per year and follows a multimor-
phological sequence, in which metaplasia evolves into 
low-grade dysplasia (LGD), high-grade dysplasia (HGD) 
and ultimately into EAC [5–7].
Previous results from whole-exome/genome sequenc-
ing of EACs demonstrated that these tumors bear a broad 
mutational spectrum; genes frequently altered are e.g. 
TP53, P16, SMAD4 and APC [8–10]. Alterations in the 
TP53 gene occur in the majority of EAC cases, however, 
only few other somatic alterations are shared between 
EACs, representing substantial intertumor heterogene-
ity. In addition, emerging evidence suggests that even an 
extensive molecular variation is present within individual 
tumors, termed intratumor heterogeneity [11–13].
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With the use of Next-generation sequencing, intratu-
mor heterogeneity has been demonstrated in several can-
cer types and even a model of branched evolution leading 
to intratumor heterogeneity has been advocated [12, 
14]. This model implicates that a single biopsy may not 
represent the total mutational burden of a tumor, which 
can explain the heterogeneous mutational spectrum 
described in EACs [8]. Conceivably, intratumor heteroge-
neity may lead to an underestimation of the mutational 
spectrum of a tumor using a single biopsy procedure, 
which might clarify the difficulties in finding and validat-
ing clinically valuable oncological biomarkers.
To date it is unknown to which extent this model of 
branched evolution for intratumor heterogeneity is appli-
cable to EAC. Therefore, the aim of this study was to 
characterize intratumor heterogeneity in EAC, by mul-
tiregional targeted sequencing on a total of 19 tumor 
regions collected from five EAC patients, including 
adjacent BE in one of them, who underwent primary 
surgical resection with curative intent. To evaluate intra-
tumor heterogeneity, DNA alterations were classified as 
homogeneous, i.e. present in all regions of the tumor, or 
heterogeneous defined as present in some regions or in 
only one region of the tumor.
Methods
Patients and specimens
Resection specimens of distal esophageal or gastro-
esophageal junction adenocarcinomas were obtained 
from five patients treated between December 2001 and 
April 2002 at the Department of Surgery, Erasmus MC 
Cancer Institute, University Medical Center Rotterdam, 
The Netherlands. All patients underwent a transhiatal 
esophagectomy, and none of them received neoadjuvant 
chemo- or radiation therapy, which is part of the current 
standard treatment of EAC [15].
Tissue samples, DNA isolation and immunohistochemistry
Tissue samples were derived from non-malignant and 
malignant areas in the fresh resection specimens and 
used according to the Code of Proper Secondary Use of 
Human Tissue in the Netherlands, as established by the 
Dutch Federation of Medical Scientific Societies (http://
www.federa.org). In addition the study was approved by 
The Medical Ethical Committee of the Erasmus MC, Uni-
versity Medical Center, Rotterdam (MEC-2016-067).
From each of the five EACs, multiple, macroscopi-
cally separated tumor regions were collected (Fig. 1). In 
addition, from one resection specimen, samples from 
an area of premalignant BE (HGD) and from a tumor 
positive lymph node (TPLN) were available for study. 
Tumor tissue areas composed of at least 50% neoplas-
tic cells (confirmed by a GI-pathologist) were manually 
microdissected from 10 to 15 hematoxylin-stained 
Sects.  (4  µm) of formalin-fixed paraffin-embedded tis-
sue blocks. DNA was extracted using proteinase K and 
5% Chelex 100 resin. TP53 immunohistochemistry was 
performed with the mouse monoclonal antibody Do-7 
(Dako, Glostrup, Denmark), according to standard 
protocols.
Ion torrent personal genome machine
Ion semiconductor sequencing was performed on the ion 
torrent personal genome machine (PGM) with a custom-
made cancer panel on DNAs extracted from the macro- 
scopically separated tumor regions according to the 
manufacturer’s protocols. In short, libraries were made 
using the Ion AmpliSeq Library Preparation Kit. A tem-
plate was prepared using the Ion OneTouch Template Kit 
and sequencing was performed with the Ion Sequencing 
Kit v2.0 on an Ion 316 chip. Data were analysed with the 
Variant Caller v2.2.3-31149 (Life Technologies, Carlsbad, 
CA, USA). Variants were called when the position was 
covered at least 100 times. Sequences of all primers and 
probes are available on request.
Mutation analysis
The custom-made cancer panel contained the genes: 
APC, P16, SMAD4 and TP53. Of all genes the total 
coding regions and the exon–intron boundaries were 
covered. Nonsynonymous somatic point mutations, 
insertions and deletions that change the protein amino 
Fig. 1 Macroscopically separated tumor regions of resection speci-
men
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acid sequence and splice site alterations were selected. 
In addition, variants present in the ESP6500si or 
1000genomes databases in ≥1% were excluded. Variants 
present in at least 30% of the called reads were considered 
reliable and were validated by Sanger sequencing accord-
ing to standard protocols.
Loss of heterozygosity analysis
To demonstrate loss of heterozygosity (LOH) of the 
genes of interest (APC, P16, SMAD4, TP53) amplicons 
for single nucleotide polymorphisms (SNPs, selected 
from dbSNP137) in these loci were added to the custom-
made cancer panel. Per locus nine SNPs were selected, 
all with a minor allele frequency of  ≥0.45 and located 
within the gene (three SNPs) and at positions ~300, ~600 
and ~900 kb centromeric and telomeric of the gene. The 
SNPs were considered heterozygous if the percentage of 
the variant in the normal DNA was within the range of 
40–60%. When at least one SNP was present heterozy-
gous in the normal DNA it was considered informa-
tive for LOH analysis. Variants present in the normal 
DNA in  <10% were considered homozygous reference 
and therefore not informative for LOH analysis, as well 
as variants present in  >90%, which were considered 
homozygous variant.
For tumor DNAs, of which the normal DNA was con-
sidered heterozygous, all SNPs with variants <40 or >60% 
were denoted as indicative for LOH. A sample was evalu-
ated as having locus LOH when ≥50% of the informative 
SNPs in that locus demonstrated LOH (variant in tumor 
DNA <40 or >60%) [16]. In addition, identified tumor sup-
pressor gene mutations also supplied information about 
possible LOH (loss of the wild type allele) by the relative 
frequency of the mutant DNA sequence compared to the 
normal wild type sequence in the tumor samples.
Intratumor heterogeneity analysis
Analysis of intratumor heterogeneity could be 
determined through mutation and LOH analysis. 
Homogeneity was signified by an identical mutation or 
the same pattern of LOH at a given gene identified in 
different tumor regions of the same tumor, whereas 
heterogeneity was signified by different mutations or 
various LOH patterns of a given gene in different regions 
of the same tumor.
Results
Targeted sequencing with a custom-made cancer panel 
was performed on DNA isolated from 19 tumor regions 
derived from the resection specimen of five EAC 
patients; all male, with a median age at the time of diag-
nosis of 70 years (range 51–78 years). Two tumors were 
localised at the gastro-esophageal junction and three in 
the distal esophagus within the background of BE. Four 
tumors were moderately differentiated, and one tumor 
was poorly differentiated. All resection margins were free 
of tumor cells. Three patients had tumor positive lymph 
nodes, without distant metastasis. Patient and tumor 
characteristics are listed in Table 1.
From one resection specimen, a region of BE (HGD) 
and a TPLN were analysed with the custom-made cancer 
panel as well. Next-generation sequencing on the PGM 
and conventional Sanger sequencing revealed 21 muta-
tions in the TP53 gene, no mutations were identified in 
APC, P16, and SMAD4. Reliable data for the LOH analy-
sis of TP53, P16, SMAD4 and APC were obtained in 92, 
92, 81 and 73% of the samples, respectively.
All five EACs showed homogeneous TP53 mutations: 
in each EAC the same TP53 mutations (nonsynonymous 
somatic point mutations or splice site alterations) were 
identified in all investigated tumor regions, all mutations 
were previous described in esophageal cancer samples 
in the COSMIC database. In addition, the TP53 muta-
tion found in a primary EAC was also identified in the 
adjacent BE and TPLN samples. LOH of TP53 occurred 
homogeneously in all informative regions of the EACs 
and in the paired EAC and BE samples with identical 
LOH patterns observed by SNP and/or mutation analysis 
Table 1 Patient and tumor characteristics
GEJAC Gastro-esophageal junction adenocarcinoma
BAC Adenocarcinoma in Barrett’s esophagus
R0 tumor free resection margin
a According to the classification of the American Joint Committee on Cancer (AJCC) Staging Manual 7th edition
Patient Tumor type Differentiation grade Resection margin TNM  stagea Tumor regions
EAC1 GEJAC Moderate R0 pT3N1Mx 5
EAC2 GEJAC Moderate/poor R0 pT3N3Mx 4
EAC3 BAC Moderate R0 pT1N0Mx 3
EAC4 BAC Moderate R0 pT3N1M0 3
EAC5 BAC Poor R0 pT2N0Mx 4
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(Fig.  2). TP53 immunohistochemistry showed homoge-
neous and strong nuclear expression in all tumor regions 
and the BE sample of the four patients with TP53 somatic 
missense mutations (Fig. 3). The tumor cells of the four 
regions derived from the EAC with a TP53 splice site 
mutation were all homogeneously negative for TP53 
expression (EAC2).
LOH of P16 occurred homogeneously in all regions 
of four informative tumors (EAC1, 2, 4, 5), and an iden-
tical LOH pattern of P16 was observed in the paired 
tumor and BE samples (Fig. 4). EAC1 and EAC3 showed 
homogeneous LOH of SMAD4 in all tumor regions, two 
tumors showed different subclones with LOH or without 
LOH of SMAD4 (EAC2 and 5), while in EAC4 no LOH 
of SMAD4 was identified. Homogeneous LOH of APC 
was observed in two tumors (EAC1 and 2), different sub-
clones with and without LOH of APC were observed in 
EAC3 and 4, whereas one tumor (EAC5) was not infor- 
mative for the APC locus (Fig. 2).
Discussion
Recent data on Next-generation sequencing of several 
tumor DNAs were supportive for the model of branched 
tumor evolution leading to intratumor heterogeneity [11, 
13]. This model describes a tumor as a tree structure, 
with the trunk representing early molecular alterations, 
which clonally expand and therefore are homogeneously 
present throughout the entire tumor, reflecting a process 
involved before and during tumor initiation and early 
development. The branches of the tree represent later 
molecular alterations, which as a result are only present 
in different subclones of the tumor, contributing to intra-
tumor heterogeneity and shaping the genome during 
tumor maintenance and progression [12, 14]. The extent 
Fig. 2 Overview of mutation and LOH analysis per tumor regions of five EACs
Fig. 3 TP53 immunohistochemistry on Barrett’s high-grade dysplasia and invasive EAC tissue
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of this branched evolution model leading to intratumor 
heterogeneity in EACs is as yet unknown.
Therefore, the aim of the current study was to charac-
terize intratumor heterogeneity in EACs, by perform-
ing multi-region, targeted sequencing on 19 tumor 
regions derived from five surgical resected EACs. Tar-
geted sequencing of commonly altered genes; TP53, P16, 
SMAD4 and APC was performed. This analysis revealed 
a clonal origin of TP53 alterations: all five EACs where 
homogeneous with regard to TP53 mutations and LOH 
of the TP53 locus, in addition the same mutation and 
pattern of LOH in TP53 was observed in a paired TPLN 
of one EAC. These results indicate that TP53 mutation 
and LOH of the TP53 locus are relatively early events in 
EAC tumorigenesis and clonally expand throughout the 
entire tumor. In concordance with this is the finding of 
the same TP53 mutation, identical pattern of LOH, and 
comparable strong nuclear TP53 expression in the paired 
primary tumor and BE case.
Mutations in the P16 gene were not observed in this 
study, however LOH of the P16 locus was identified 
in all EACs. Four EACs had a homogeneous P16 locus 
LOH pattern, while one EAC was heterogeneous for 
P16 LOH. In addition, an identical pattern of P16 locus 
LOH was present in the paired primary EAC and BE 
case, suggesting that LOH of P16 is an early alteration, 
clonally expanding throughout the tumor. No mutations 
were identified in SMAD4 and APC, but LOH of these 
genes was observed in a heterogeneous pattern within 
the EACs. Some EACs showed homogeneous LOH 
of SMAD4 and/or APC, one EAC showed no LOH of 
SMAD4 at all, while the remaining EACs showed differ-
ent subclones: some with LOH of SMAD4 and/or APC 
and others without LOH of these loci. In addition, no 
LOH of SMAD4 and APC was found in the BE sample, 
indicating a late occurrence of these alterations, reflect-
ing intratumor heterogeneity of EACs.
Taken together, the results of the current study suggest 
that both homogeneous and heterogeneous intratumoral 
molecular alterations are present in EACs. A homogene-
ously present TP53 mutation and LOH of the TP53 locus 
as well as LOH of the P16 locus in the primary tumor 
were also found in the adjacent BE sample, indicating that 
the earliest molecular alterations can already be present 
in the premalignant lesion (BE) and from there on clon-
ally expand throughout the entire tumor. Temporarily, no 
multiregion sequencing of EACs was performed before. 
Alterations in TP53 were described previously in the 
sequential of BE (HGD) and EAC, and in addition were 
found to be present in a major clone, which also indicates 
clonal expansion of TP53 as an early alteration [17].
The presence of alterations in BE is in accordance with 
previous studies, showing that multiple BE crypts con-
tain different clones with alterations competing with 
each other [18, 19], of which one progenitor clone with a 
selective growth advantage will expand clonally and will 
create a field in which other (pre)malignant alterations 
might arise [19]. Several studies on P16 have reported 
clonal expansion of P16 alterations in all regions of BE 
segments, and it has been suggested that expansion of 
TP53 alterations occurs only in a background of P16 
altered clones [20]. However, others described progeni-
tor clones containing TP53 alterations alone or in com-
bination with P16 alterations present at many levels of BE 
segments [21]. Leedham et al. [18] concluded that BE was 
genetically heterogeneous, however they observed iden-
tical TP53 mutations in multiple BE crypts, indicating 
widespread and far-reaching clonal expansion as a con-
sequence of the strong selective advantage that absence 
of TP53 function supposedly provide. Recently, a study 
on cytochrome c oxidase (CCO) deficient cells in BE con-
firmed the concept of clonal expansion of BE, probably 
by fission of BE glands [22].
Conceivably, intratumor heterogeneity can cause 
tumor sample bias using single biopsy approaches, since 
it may underestimate the mutation spectrum of a tumor. 
This could contribute to difficulties in identifying and 
validating biomarkers, which are desirable to identify BE 
patients with a high risk for neoplastic progression. Fur-
thermore, intratumor heterogeneity may contribute to 
therapy resistance: if the actionable target of treatment 
is only present in a subclone of the tumor, than targeting 
Fig. 4 P16 LOH SNP analysis of normal, Barrett’s high-grade dysplasia and concomitant EAC sample
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this genetic alteration may not have an impact on the 
entire tumor. This concept might explain the diversity in 
responders and non-responders after neoadjuvant chem-
oradiotherapy in EACs [23].
Conclusions
Recent studies on EAC reveal extensive intertumor 
heterogeneity concerning molecular alterations with dif-
ferent studies showing different recurrently mutated 
genes. Therefore, the genes found frequently mutated 
in several studies were investigated in the current study 
[8–10, 17]. Even though the sample size is small, and tar-
geted sequencing of only commonly mutated genes was 
performed, the current study provides evidence that 
although intratumor heterogeneity is present in EACs, 
known driver alterations in TP53 and P16 were homo-
geneously present in all five primary EACs, indicating 
clonal cellular expansion. Studies with larger cohorts and 
extensive genome sequencing are needed to fully charac-
terize intratumor heterogeneity in EACs and in addition, 
to understand the impact of intratumor heterogeneity on 
current clinical outcome of both BE and EAC patients.
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